Document is current

Article History

Received: 24 February 2024

Revised: 9 May 2024

Accepted: 24 June 2024

First Online: 2 August 2024

Compliance with ethical standards

:

: The scientific guarantor of this publication is Dr. Christiaan G. Overduin.

: The authors of this manuscript declare relationships with the following companies: M.R.M. Medtronic-Covidien, Johnson & Johnson, Angiodynamics, Philips, Immunophotonics, and Guerbet. R.B. with Interventional Systems. The remaining authors declare no conflicts of interest.

: One of the authors has significant statistical expertise.

: Only if the study is on human subjects: written informed consent was waived by the Institutional Review Board. For this retrospective study, informed consent to use and exchange pseudonymized data was waived by the local institutional review board at each institution (2018–2053; 2020.077; 1316/2021) for all study participants. All data was shared under data sharing agreements (A20-0423; A21-0442) in compliance with local regulations.

: Institutional Review Board approval was obtained.

: In a prior study (Laimer 2021—PMID: 33447860), we reported on 45 of 113 patients included in the current study. The previous study was a single-center study utilizing one confirmation software (Ablation-fit). The current study expands on this by having a multicenter cohort and all data analyzed by a second confirmation software, providing a significantly increased study population and additional and new analyses per software, including inter-software agreement. The extent of overlap has been explicitly mentioned in the Materials and Methods section of the manuscript (Page 4, 1st paragraph), including reference to the prior study.

: